Replies to post #10741 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

…FDA rarely rejects a generic but rather just lets them collect dust in a corner. [MYL] will be a cloud over generic copax no matter what happens.

Not unduly or to the same degree as with Lovenox. On Copaxone, MNTA gets a 50% profit split with NVS regardless of how many generic products are on the market.